Skip to main content
. Author manuscript; available in PMC: 2021 Dec 7.
Published in final edited form as: Anticancer Res. 2020 Dec 7;40(12):6637–6647. doi: 10.21873/anticanres.14688

Table I.

Target-based assay activity of (+)-betulin in MDA-MB-231 breast cancer cells.

Compound SRBa NF-κBb MTPc
(+)-Betulin 9.5 3.9 6.5
Paclitaxeld 0.3
Rocaglamided 0.2
Staurosporined 0.5
a

IC50 value (μM) in MDA-MB-231breast cancer cells. SRB assay=sulforhodamine B assay

b

IC50 value (μM) for inhibition of nuclear factor kappa B (NF-κB p65).

c

EC50 value (μM) for loss of mitochondrial transmembrane potential (MTP).

d

Positive controls.